1. Inicio
  2. Proyectos y Estudios
  3. EFECTO DE LA ACTIVACION DEL RECEPTOR PPARƒ×/RXR COMO POSIBLE TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER. PAPEL DE LA GENISTEINA. ESTUDIO GENIAL.

EFECTO DE LA ACTIVACION DEL RECEPTOR PPARƒ×/RXR COMO POSIBLE TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER. PAPEL DE LA GENISTEINA. ESTUDIO GENIAL.

Datos básicos

Código:
INC-GEN-2013-01
Protocolo:
INC-GEN-2013-01
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2018
Año de finalización:
2018
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

JOSE VIÑA RIBES

Resultados del Ensayo Clínico

A cross-sectional and longitudinal study on the protective effect of bilingualism against dementia using brain atrophy and cognitive measures.

Costumero V; (...); Ávila C

Article. 10.1186/s13195-020-0581-1. 2020


A novel TRMT5 mutation causes a complex inherited neuropathy syndrome: the role of nerve pathology in defining a demyelinating neuropathy.

Argente-Escrig, Herminia; (...); Sevilla, Teresa

Article. 10.1111/nan.12817. 2022


A study of the phenotypic variability and disease progression in Laing myopathy through the evaluation of muscle imaging.

Muelas N; (...); Vilchez JJ

Article. 10.1111/ene.14630. 2021


Advances in the early diagnosis of amyotrophic lateral sclerosis.

Garcia-Casanova, Pilar H, Vazquez-Costa, Juan F

Article. 10.1080/14737175.2025.2471556. 2025


Amyloid brain-dedicated PET images can diagnose Alzheimer's pathology with Centiloid Scale.

Gandia-Ferrero MT; (...); Martí-Bonmatí L

Article. 10.1016/j.ejmp.2024.103345. 2024


Analysis of the diagnostic pathway and delay in patients with amyotrophic lateral sclerosis in the Valencian Community.

Vázquez-Costa JF; (...); Sevilla-Mantecón T

Article. 10.1016/j.nrl.2018.03.026. 2018


Analysis of the diagnostic pathway and delay in patients with amyotrophic lateral sclerosis in the Valencian Community.

Vazquez-Costa, J F; (...); Sevilla-Mantecon, T

Article. 10.1016/j.nrleng.2018.03.023. 2021


Angiotensin II Receptor Blockers Reduce Tau/ASS42 Ratio: A Cerebrospinal Fluid Biomarkers' Case-Control Study.

Garcia-Lluch, Gemma; (...); Chafer-Pericas, Consuelo

Article. 10.3390/pharmaceutics15030924. 2023


Artificial Intelligence on FDG PET Images Identifies Mild Cognitive Impairment Patients with Neurodegenerative Disease.

Prats-Climent, Joan; (...); Marti-Bonmati, Luis

Article. 10.1007/s10916-022-01836-w. 2022


Assessment of apolipoprotein E genotype for ß-amyloid status prediction.

Peña-Bautista C; (...); Chafer-Pericas, Consuelo

Article. 10.2174/1567205019666211223141524. 2021


Assessment of COVID-19 lockdown effect on early Alzheimer Disease progression.

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.1007/s00415-023-11899-5. 2023


Assessment of lipid peroxidation and artificial neural network models in early Alzheimer Disease diagnosis.

Peña-Bautista C; (...); Cháfer-Pericás C

Article. 10.1016/j.clinbiochem.2019.07.008. 2019


Assessment of Lipid Peroxidation in Alzheimer's Disease Differential Diagnosis and Prognosis.

Ferre-Gonzalez, Laura; (...); Chafer-Pericas, Consuelo

Article. 10.3390/antiox11030551. 2022


Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.

Álvarez-Sánchez L; (...); Cháfer-Pericás C

Article. 10.3390/ijms24021226. 2023


Assessment of Screening Approach in Early and Differential Alzheimer's Disease Diagnosis.

Ferré-González L; (...); Cháfer-Pericás C

Article. 10.3390/antiox10111662. 2021


Associations between antidiabetic medications and cerebrospinal fluid biomarkers of Alzheimer's disease.

Garcia-Lluch, Gemma; (...); Chafer-Pericas, Consuelo

Article. 10.1177/13872877241304995. 2024


Attitudes toward seeking professional help among patients with early Alzheimer's disease

Villarejo-Galende, A.; (...); Maurino, J.

Meeting Abstract. 2023


Awareness of Diagnosis in Persons with Early-Stage Alzheimer's Disease: An Observational Study in Spain.

Villarejo-Galende, Alberto; (...); Maurino, Jorge

Article. 10.1007/s40120-022-00367-3. 2022


Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions.

García-Lluch G; (...); Cháfer-Pericás C

Article. 10.14283/jpad.2024.16. 2024


Clinical and genetic characteristics of 21 Spanish patients with biallelic pathogenic SPG7 mutations.

Baviera-Muñoz R; (...); Espinós C

Article. 10.1016/j.jns.2021.118062. 2021


Clinical and Magnetic Resonance Imaging features of a series of 11 Spanish patients who carry mutations in the BICD2 gene

Carrera, MF; (...); Sevilla, T

Meeting Abstract. 2018


Clinical features, mutation spectrum and factors related to reaching molecular diagnosis in a cohort of patients with distal myopathies.

Muelas, Nuria; (...); Vilchez, Juan J

Article. 10.1007/s00415-024-12821-3. 2025


Clinical spectrum of BICD2 mutations.

Frasquet M; (...); Sevilla T

Article. 10.1111/ene.14173. 2020


Clinical trials in pediatric ALS: a TRICALS feasibility study.

Kliest T; (...); Van Den Berg LH

Article. 10.1080/21678421.2021.2024856. 2022


Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer Disease.

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.1111/eci.13910. 2022


Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer's Disease Differential Diagnosis

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.3390/antiox9080649. 2020


COGNITIVE FUNCTION FOLLOWING AN INTRACEREBRAL HEMORRHAGE ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY.

Gimenez, C; (...); Lago, A

Meeting Abstract. 2020


Characterising the phenotype and mode of inheritance of patients with inherited peripheral neuropathies carrying MME mutations

Lupo, V; (...); SEVILLA, T

Article. 10.1136/jmedgenet-2018-105650. 2018


Characterizing SOD1 mutations in Spain. The impact of genotype, age, and sex in the natural history of the disease.

Vazquez-Costa, Juan F.; (...); Garcia-Redondo, Alberto

Article. 10.1111/ene.15661. 2022


Charcot-Marie-Tooth disease due to MORC2 mutations in Spain

Sivera R; (...); Sevilla T

Article. 10.1111/ene.15001. 2021


Defining Alzheimer's Disease through Proteomic CSF Profiling.

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.1021/acs.jproteome.4c00590. 2024


Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)

Pitarch Castellano, I; (...); Vazquez-Costa, J. F.

Article. 10.1016/j.nrl.2021.07.008. 2022


Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus).

Pitarch Castellano I; (...); Vázquez-Costa JF

Practice Guideline. 10.1016/j.nrleng.2021.07.002. 2022


Depression and Suicide Risk in Mild Cognitive Impairment: The Role of Alzheimer's Disease Biomarkers

Ferrer-Cairols, Ines; (...); Salvador, Alicia

Article. 10.7334/psicothema2022.103. 2022


Descriptive analysis of the spinal muscular atrophy population treated with Nusinersen included in the CuidAME project

Sotoca Fernandez, J.; (...); Fernandez-Garcia, M.

Meeting Abstract. 10.1016/j.nmd.2024.07.462. 2024

  • Open Access.

Design and Validation of a Clinical Outcome Measure for Adolescents and Adult Patients with Spinal Muscular Atrophy: SMA Life Study Protocol

Rebollo, Pablo; (...); Vazquez-Costa, Juan F.

Article. 10.1007/s40120-023-00571-9. 2024


Design of a Non-Interventional Study to Validate a Set of Patient- and Caregiver-Oriented Measurements to Assess Health Outcomes in Spinal Muscular Atrophy (SMA-TOOL Study).

Madruga-Garrido M; (...); Maurino J

Article. 10.1007/s40120-020-00229-w. 2021


Diagnostic delay and pathway analysis in paediatric Charcot-Marie-Tooth disease

Argente-Escrig, H; (...); Mantecon, MTS

Meeting Abstract. 2019


Diagnostic Efficacy of Genetic Studies in a Series of Hereditary Cerebellar Ataxias in Eastern Spain.

Baviera-Munoz, Raquel; (...); Aller, Elena

Article. 10.1212/NXG.0000000000200038. 2022


Discordant Amyloid Status Diagnosis in Alzheimer's Disease.

García-Vallés L; (...); Cháfer-Pericás C

Article. 10.3390/biomedicines10112880. 2022


Distal hereditary motor neuropathies: mutation spectrum and genotype-phenotype correlation.

Frasquet, Marina; (...); Lupo, Vincenzo

Article. 10.1111/ene.14700. 2021


Do we really need to calculate a minimal important difference for ALSFRS-R?: A letter in response to 'Clinically meaningful change: evaluation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) and the ALSFRS-R' published in Vol. 24(3-4), pp. 311-316

Vázquez-Costa JF

Article. 10.1080/21678421.2023.2248199. 2024


Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms241814151. 2023


Early neurotransmission impairment in non-invasive Alzheimer Disease detection

Pena-Bautista, Carmen; (...); Cháfer-Pericás C

Article. 10.1038/s41598-020-73362-z. 2020


Effects of bilingualism on white matter atrophy in mild cognitive impairment: a diffusion tensor imaging study.

Marin-Marin L; (...); Ávila C

Article. 10.1111/ene.14135. 2020


Emotion recognition and baseline cortisol levels relationship in early Alzheimer Disease.

Ferrer-Cairols, I.; (...); Chafer-Pericas, C.

Article. 10.1016/j.biopsycho.2023.108511. 2023


Epigenomics and Lipidomics Integration in Alzheimer Disease: Pathways Involved in Early Stages.

Peña-Bautista C; (...); Chafer-Pericas, Consuelo

Article. 10.3390/biomedicines9121812. 2021


Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia.

Barceló MA; (...); Saez M

Article. 10.1038/s41598-021-85395-z. 2021


Facial Onset Sensory and Motor Neuronopathy New Cases, Cognitive Changes, and Pathophysiology

de Boer, EMJ; (...); van Es, MA

Review. 10.1212/CPJ.0000000000000834. 2021


Facial onset sensory and motor neuronopathy: a motor neuron disease with an oligogenic origin?

Vazquez-Costa, JF; (...); Sevilla, T

Article. 10.1080/21678421.2019.1582671. 2019


Fast Declining Prediction in Alzheimer's Disease from Early Clinical Assessment.

Álvarez-Sánchez L; (...); Pericás CC

Article. 10.2174/011570159X332930240925095423. 2024


Fatigue, pain, breathing, voice, fatigability, sleep, rest and vulnerability as meaningful outcomes in SMA care: the patients ' and caregivers' voice

Povedano, M.; (...); Rebollo, P.

Meeting Abstract. 10.1016/j.nmd.2022.07.209. 2022


Free radicals in Alzheimer's disease: Lipid peroxidation biomarkers

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Review. 10.1016/j.cca.2019.01.021. 2019


Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project

Moreno-Grau, S; (...); GR ACE Study Grp

Article. 10.1016/j.jalz.2019.06.4950. 2019


Imaging Biomarkers for the Diagnosis and Prognosis of Neurodegenerative Diseases. The Example of Amyotrophic Lateral Sclerosis

Mazon, M; (...); Marti-Bonmati, L

Review. 10.3389/fnins.2018.00784. 2018


Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Cerda Alberich, Leonor; (...); Marti-Bonmati, Luis

Editorial Material. 10.1007/978-1-0716-1712-0_20. 2022


Impact of SARS-CoV-2 infection and COVID-19 pandemic on the morbidity and mortality of amyotrophic lateral sclerosis patients in Valencia, Spain

Garcia-Casanova, Pilar H.; (...); Vazquez-Costa, Juan F.

Article. 10.1111/ene.16465. 2024


Improving Care and Empowering Adults Living with SMA: A Call to Action in the New Treatment Era.

Walter MC; (...); Servais L

Article. 10.3233/JND-200611. 2021


Insights from a 7-Year Dementia Cohort (VALCODIS): ApoE Genotype Evaluation.

Baquero, Miguel; (...); Chafer-Pericas, Consuelo

Article. 10.3390/jcm13164735. 2024


Insights into phenotypic variability caused by GARS1 pathogenic variants.

Jiménez-Jiménez J; (...); Sivera R

Article. 10.1111/ene.16416. 2024


Intermediate Repeat Expansion in the ATXN2 Gene as a Risk Factor in the ALS and FTD Spanish Population.

Borrego-Hernandez, Daniel; (...); Garcia-Redondo, Alberto

Article. 10.3390/biomedicines12020356. 2024


Isoprostanoids Levels in Cerebrospinal Fluid Do Not Reflect Alzheimer's Disease

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.3390/antiox9050407. 2020


La reserva cognitiva como factor modulador del impacto de la cirugía sobre la memoria visual y la denominación en pacientes con epilepsia del lóbulo temporal.

Cano-Lopez, I; (...); Gonzalez-Bono, E

Article. 10.33588/rn.7308.2021109. 2021


Lifesaving Treatments for Spinal Muscular Atrophy: Global Access and Availability

Armengol, Victor D.; (...); Roy, Bhaskar

Meeting Abstract. 2023


Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability.

Armengol, Victor D; (...); Roy, Bhaskar

Article. 10.1212/CPJ.0000000000200224. 2024


Lipid Peroxidation Assessment in Preclinical Alzheimer Disease Diagnosis

Pena-Bautista, Carmen; (...); Cháfer-Pericás C

Article. 10.3390/antiox10071043. 2021


Lipid peroxidation biomarkers correlation with medial temporal atrophy in early Alzheimer Disease

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.1016/j.neuint.2019.104519. 2019


Lipid peroxidation in neurodegeneration.

Peña-Bautista C; (...); Cháfer-Pericás C

Review. 10.1016/j.cca.2019.07.037. 2019


Lipids as early and minimally invasive biomarkers for Alzheimer disease.

Casas-Fernandez, Esther; (...); Chafer-Pericas, Consuelo

Article. 10.2174/1570159X19666211102150955. 2021


Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022


Measuring Outcomes in Adults with Spinal Muscular Atrophy - Challenges and Future Directions - Meeting Report.

Sansone VA; (...); Hagenacker T

Article. 10.3233/JND-200534. 2020


MEASURING THE EXPERIENCE OF LIVING WITH SPINAL MUSCULAR ATROPHY: THE ROLE OF THE SMA INDEPENDENCE SCALE

Vazquez, J. F.; (...); Madruga, M.

Meeting Abstract. 2022


Medical help-seeking intentions among patients with early Alzheimer's disease

Villarejo-Galende, Alberto; (...); Maurino, Jorge

Article. 10.3389/fpsyt.2023.1290002. 2023


Metabolomics study to identify plasma biomarkers in alzheimer disease: ApoE genotype effect.

Peña-Bautista C; (...); Cháfer-Pericás C

Article. 10.1016/j.jpba.2019.113088. 2020


Minimal detectable change and minimal clinically important difference in spinal muscular atrophy patients.

Vázquez-Costa JF, Hervás D

Letter. 10.1111/ene.14780. 2021


Misfolded alpha-synuclein detection by RT-QuIC in dementia with lewy bodies: a systematic review and meta-analysis.

Peña-Bautista C; (...); Ferreira D

Article. 10.3389/fmolb.2023.1193458. 2023


Moral reasoning and moral conflict in patients of the amyotrophic lateral sclerosis - Frontotemporal dementia spectrum.

Serrano-Pastor, Lucas; (...); Vazquez-Costa, Juan F

Article. 10.1080/17470919.2020.1850521. 2020


Mutations in MME cause autosomal recessive late-onset CMT type-2 disease

Carrera, MF; (...); Sevilla, T

Meeting Abstract. 2018


Natural history data in adults with SMA

Vazquez-Costa, JF

Letter. 10.1016/S1474-4422(20)30183-6. 2020


Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen

Andres-Benito, Pol; (...); Povedano, Monica

Article. 10.3390/ijms25073810. 2024


Neuropsychological assessment and cortisol levels in biofluids from early Alzheimer's disease patients

Pena-Bautista, C.; (...); Chafer-Pericas, C.

Article. 10.1016/j.exger.2019.05.007. 2019


New approach for early and specific Alzheimer disease diagnosis from different plasma biomarkers.

Forte, Anabel; (...); Chafer-Pericas, Consuelo

Article. 10.1016/j.cca.2024.117842. 2024


New insights into the genetic etiology of Alzheimer's disease and related dementias

Bellenguez, Celine; (...); CHARGE

Article. 10.1038/s41588-022-01024-z. 2022


New insights into the pathophysiology of fasciculations in amyotrophic lateral sclerosis: An ultrasound study

Vazquez-Costa, JF; (...); Sevilla, T

Article. 10.1016/j.clinph.2018.09.014. 2018


New screening approach for Alzheimer's disease risk assessment from urine lipid peroxidation compounds.

Peña-Bautista C; (...); Chafer-Pericas, C

Article. 10.1038/s41598-019-50837-2. 2019


Novel Ultrasensitive Detection Technologies for the Identification of Early and Minimally Invasive Alzheimer's Disease Blood Biomarkers.

Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo

Article. 10.3233/JAD-215093. 2022


Nusinersen in adult patients with 5q spinal muscular atrophy: Amulticenter observational cohorts' study.

Vazquez-Costa, Juan F.; (...); Hervas, David

Article. 10.1111/ene.15501. 2022


Obstructive sleep apnea and Alzheimer's disease-related cerebrospinal fluid biomarkers in mild cognitive impairment.

Díaz-Román M; (...); Gómez E

Article. 10.1093/sleep/zsaa133. 2021


Omics-based Biomarkers for the Early Alzheimer Disease Diagnosis and Reliable Therapeutic Targets Development

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Review. 10.2174/1570159X16666180926123722. 2019


Oxidative Damage of DNA as Early Marker of Alzheimer's Disease.

Peña-Bautista C; (...); Cháfer-Pericás C

Article. 10.3390/ijms20246136. 2019


Pediatric inherited peripheral neuropathy: a prospective study at a Spanish referral center

Argente-Escrig H; (...); Sevilla T

Article. 10.1002/acn3.51432. 2021


Person-centered Assessment in Early Alzheimers Disease (P1-1.Virtual)

Villarejo Galende, Alberto; (...); Maurino, Jorge

Meeting Abstract. 2022


Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study

Timmers, M; (...); Engelborghs, S

Article. 10.1186/s13195-018-0415-6. 2018


Phenotypical features of two patients diagnosed with PHARC syndrome and carriers of a new homozygous mutation in the ABHD12 gene

Frasquet, M; (...); Sevilla, T

Article. 10.1016/j.jns.2018.02.021. 2018


Plasma alterations in cholinergic and serotonergic systems in early Alzheimer Disease: Diagnosis utility.

Peña-Bautista C; (...); Cháfer-Pericás C

Article. 10.1016/j.cca.2019.10.023. 2020


Plasma isoprostanoids assessment as Alzheimer's disease progression biomarkers.

Peña-Bautista C; (...); Cháfer-Pericás C

Article. 10.1111/jnc.15183. 2020


Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer Disease detection

Pena-Bautista, C; (...); Chafer-Pericas, C

Article. 10.1016/j.freeradbiomed.2018.06.038. 2018


Plasma Lipidomics Approach in Early and Specific Alzheimer's Disease Diagnosis.

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.3390/jcm11175030. 2022


Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.1016/j.jprot.2019.04.008. 2019


Presenilin-1 Mutations Are a Cause of Primary Lateral Sclerosis-Like Syndrome

Vazquez-Costa, JF; (...); SEVILLA, T

Article. 10.3389/fnmol.2021.721047. 2021


Prognostic value of cerebrospinal fluid biomarkers in mild cognitive impairment due to Alzheimer disease.

López-Cuevas R; (...); Cháfer-Pericás C

Article. 10.1016/j.nrl.2020.07.026. 2020


Prognostic value of cerebrospinal fluid biomarkers in mild cognitive impairment due to Alzheimer disease.

Lopez-Cuevas, R; (...); Chafer-Pericas, C

Article. 10.1016/j.nrleng.2020.07.024. 2023


Quantitative neuromuscular ultrasound analysis as biomarkers in amyotrophic lateral sclerosis

Rios-Diaz, J; (...); Martinez-Paya, JJ

Article. 10.1007/s00330-018-5943-8. 2019


Recent evidence in epigenomics and proteomics biomarkers for early and minimally invasive diagnosis of Alzheimer's and Parkinson's diseases.

Mayo, Sonia; (...); Chafer-Pericas, Consuelo

Review. 10.2174/1570159X19666201223154009. 2020


Relationship between neuroimaging and emotion recognition in Mild Cognitive Impairment patients.

Gandia-Ferrero, Maria Teresa; (...); Marti-Bonmati, Luis

Article. 10.1016/j.bbr.2023.114844. 2024


Relationship between Plasma Lipid Profile and Cognitive Status in Early Alzheimer Disease.

Pena-Bautista, Carmen; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms25105317. 2024


Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease

Timmers, M; (...); Streffer, JR

Article. 10.1016/j.neurobiolaging.2019.03.016. 2019


Risdiplam in non-sitter patients aged 16years and older with 5q spinal muscular atrophy.

Nungo Garzon, Nancy Carolina; (...); Vazquez-Costa, Juan F

Article. 10.1002/mus.27804. 2023


Role of the nigrosome 1 absence as a biomarker in amyotrophic lateral sclerosis

Isabel Moreno-Gambin, Maria; (...); Vázquez-Costa JF

Article. 10.1007/s00415-021-10729-w. 2021


SONOELASTOGRAPHY FOR THE ASSESSMENT OF MUSCLE CHANGES IN AMYOTROPHIC LATERAL SCLEROSIS: RESULTS OF A PILOT STUDY

Martinez-Paya, JJ; (...); Vazquez-Costa, JF

Article. 10.1016/j.ultrasmedbio.2018.08.009. 2018


Spinal Muscular Atrophy Update in Best Practices: Recommendations for Diagnosis Considerations.

Schroth, Mary; (...); Vazquez-Costa, Juan F.

Article. 10.1212/CPJ.0000000000200310. 2024


STATISTICAL SOLUTIONS FOR ANALYTIC CHALLENGES IN REGISTRIES FOR HTA-PURPOSES

Fekete, I; (...); Volmer, T

Meeting Abstract. 2020


Stress and neurodegeneration.

Peña-Bautista C; (...); Cháfer-Pericás C

Review. 10.1016/j.cca.2020.01.019. 2020


The cross-sectional area of the median nerve: An independent prognostic biomarker in amyotrophic lateral sclerosis

Martinez-Paya, J. J.; (...); Vazquez-Costa, J. F.

Article. 10.1016/j.nrl.2022.01.008. 2024


The cross-sectional area of the median nerve: An independent prognostic biomarker in amyotrophic lateral sclerosis.

Martinez-Paya, J J; (...); Vazquez-Costa, J F

Article. 10.1016/j.nrleng.2024.07.003. 2024


The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's Disease in APOE epsilon 4 Non-carriers

Sanchez-Juan, P; (...); DEGESCO Consortium

Article. 10.3389/fnagi.2019.00327. 2019


The width of the third ventricle associates with cognition and behaviour in motor neuron disease

Vazquez-Costa, JF; (...); Sevilla, T

Article. 10.1111/ane.13022. 2019


Treatment of patients with spinal muscular atrophy 5q: Towards a new protocol.

Gomez-Andres, D., Martinez-Moreno, M., Vazquez-Costa, J. F.

Letter. 10.1016/j.nrl.2020.10.003. 2021


Treatment of patients with spinal muscular atrophy 5q: towards a new protocol.

Gómez-Andrés D, Martínez-Moreno M, Vázquez-Costa JF

Letter. 10.1016/j.nrleng.2020.10.005. 2021


Treatment of spinal muscular atrophy in European countries: A call to action

Vazquez-Costa, Juan F.; (...); Cattinari, Maria Grazia

Article. 10.1111/ene.15522. 2022


Ultrasound-guided lumbar puncture for nusinersen administration in spinal muscular atrophy patients.

Veiga-Canuto D; (...); Aparici F

Article. 10.1111/ene.14586. 2021


Urinary symptoms in patients with amyotrophic lateral sclerosis.

Vázquez-Costa JF, Arlandis S

Letter. 10.1016/j.nrl.2019.01.003. 2020


Validated analytical method to determine new salivary lipid peroxidation compounds as potential neurodegenerative biomarkers.

Peña-Bautista C; (...); Cháfer-Pericás C

Article. 10.1016/j.jpba.2018.11.043. 2019


Validation of a Set of Instruments to Assess Patient- and Caregiver-Oriented Measurements in Spinal Muscular Atrophy: Results of the SMA-TOOL Study.

Vazquez-Costa, Juan F.; (...); Madruga-Garrido, Marcos

Article. 10.1007/s40120-022-00411-2. 2022


Validation of Neuromyotype: A smart keyboard for the evaluation of spinal muscular atrophy patients

Lizandra Cortes, P.; (...); Vazquez-Costa, J. F.

Article. 10.1016/j.nrl.2022.05.004. 2024


Validation of Neuromyotype: A smart keyboard for the evaluation of spinal muscular atrophy patients.

Cortes, P Lizandra; (...); Vázquez-Costa JF

Article. 10.1016/j.nrleng.2022.05.001. 2022


Campos de estudio

Compartir